In a new study from consulting firm Numerof & Associates and the Jefferson College of Population Health, more than half of healthcare providers said that they get no more than 20 percent of revenue from risk-based contracts.
This week for MedHeads we’ll be joined for this discussion by Dr. Dan Peterson, founder of Teqqa, which is focused on improving the treatment of infectious diseases and addressing the growing problem of antibiotic resistance, as well as, Lucas Felt president and CEO of The Medical Memory and Steve Kraus of Bessemer Venture Partners.
The regenerative medicine company says it has a small molecule in the works that could help regrow brain cells in Alzheimer’s and Parkinson’s disease.
In an effort to increase ALS research, Biogen is contributing $5 million – and offering to match more – to entice researchers to conduct basic science and therapeutics research in the debilitating disease.
Perhaps it’s not surprising that misdiagnosis, delayed diagnosis and other assessment-related issues were so prevalent in cardiology.
Dreamit Health has had 40 startups take part in its accelerator since its start.
23andMe and Celmatix are combining forces to understand the genomic underpinnings of infertility.
In a phone interview, Huber shared that he believes his experience with Google, in different areas over 13 years, set him up to be very conscious of analytics and looking at specific data, which will be an asset to Grail in determining the efficacy of future clinical trials.
With the future of the federal electronic health records incentive program now up in the air, a bill that addresses major complaints about Meaningful Use seems to be on the fast track to passage.
Promising contenders to buoy the Alzheimer’s market include Merck’s verubecestat, Biogen’s aducanumab and VTV Therapeutis’ azeliragon.
The telemedicine business claims it tripled sales last year.
Also, CTI BioPharma Corp said the U.S Food and Drug Administration has put a full clinical hold on the company’s investigational new drug application for pacritinib.
Cambridge startup Yumanity Therapeutics just closed out an impressive $45 million Series A – meant […]
CorMatrix Cardiovascular has announced FDA 510(k) for its Tyke extracellular matrix biomaterial for use in neonates and infants.
A wearable alone won’t solve the nation’s obesity problem or help people manage congestive heart failure. Data needs context, a Silicon Valley startup executive explained.
There is a fundamental transition happening right now in healthcare: the move from fee-for-service to fee-for-performance. While it means better and more efficient patient care, many providers are skeptical and extremely concerned with the impact on their bottom line. And it’s so much more than an accounting change. It’s a complete mindset change. Read more
This stance on keeping drug pricing aloft helps Biogen CEO George Scangos rationalize the ever-increasing price of its multiple sclerosis drug Avonex.
DoD officials this month denied appeals by groups led by IBM, Computer Sciences Corp., Amazon and General Dynamics, against a $50.7 million no-bid hosting contract to primary DHMSM contractor Leidos and partner Cerner, originally awarded in December.
Amgen is stepping up by creating a new journal to make sure that study publications are being confirmed and studies are replicated.